EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Prevalence, prognostic and clinicopathological value of HIF-1α in glioblastoma patients: a systematic review and meta-analysis

Hao Li, Xiaochen Niu, Rui Cheng

Neurosurgical Review · 2024

DOI: 10.1007/s10143-024-03087-4 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Neurosurgical Review, 2024. Verfasst von Hao Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Health Sciences, The University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Glioblastoma, Hypoxia-Inducible Factor 1, alpha Subunit, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several studies have investigated the role of HIF-1α in predicting the prognosis of patients with glioblastoma, yielding contradictory results. Therefore, we performed a meta-analysis to document the correlation between HIF-1α and glioblastoma in individuals diagnosed with glioblastoma. We searched the PubMed, Cochrane Library, EMBASE, and Web of Science by January 25, 2024. Hazard Ratio (HR) was used to evaluate the relationship between HIF-1α and survival outcome, and Odds Ratio (OR) was adopted for tumor features.There was incorporation of nine observational studies with 607 individuals. The total prevalence of HIF-1α (higher than cut-off values) among individuals with glioblastoma was 0.72 (95% confidence interval (CI) = 0.68-0.75, I2 = 95.1%). There is a strong association between increased levels of HIF-1α in tumour tissues and shorter Overall Survival (OS) (HR = 1.82, 95% CI = 1.41-2.34, I2 = 13.7%). Subgroup analysis also indicated a correlation between higher levels of HIF-1α and reduced OS, specifically in the Asian population (HR = 1.48, 95% CI = 1.13-1.83, I2 = 41.5%). In addition, there was a correlation between HIF-1α and age (older vs. younger, OR = 2.19, 95% CI = 1.25-3.86, P = 0.260). High levels of HIF-1α expression were associated with poorer survival outcomes and other clinicopathological characteristics of glioblastoma. Integrating HIF-1α into prognostic tools for glioblastoma aids in predicting survival, categorising risk, and advising patients on suitable treatment regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaHypoxia-Inducible Factor 1, alpha SubunitBrain NeoplasmsHumansPrognosisPrevalenceBiomarkers, Tumor

Stichwörter der Autor:innen

GlioblastomaGliomaHIF-1αMeta-analysisPrognosisSystematic review

Substanzen

Hypoxia-Inducible Factor 1, alpha SubunitHIF1A protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • School of Health Sciences, The University of Manchester, Manchester, UK.
  • The Fifth Clinical Medical College of Shanxi Medical University, Taiyuan, China.
  • Shanxi Provincial Key Laboratory of Intelligent, Big Data and Digital Neurosurgery, Taiyuan, China.
  • Shanxi Provincial Key Laboratory of Intelligent Brain Tumor, Taiyuan, China.
  • The Fifth Clinical Medical College of Shanxi Medical University, Taiyuan, China. neurocheng@163.com.
  • Shanxi Provincial Key Laboratory of Intelligent, Big Data and Digital Neurosurgery, Taiyuan, China. neurocheng@163.com.

Zitieren

APA

Li, H., Niu, X., & Cheng, R. (2024). Prevalence, prognostic and clinicopathological value of HIF-1α in glioblastoma patients: a systematic review and meta-analysis. Neurosurgical Review. https://doi.org/10.1007/s10143-024-03087-4

Vancouver

Li H, Niu X, Cheng R. Prevalence, prognostic and clinicopathological value of HIF-1α in glioblastoma patients: a systematic review and meta-analysis. Neurosurgical Review. 2024. doi:10.1007/s10143-024-03087-4

BibTeX
@article{Li2024,
  author = {Li, Hao and Niu, Xiaochen and Cheng, Rui},
  title = {Prevalence, prognostic and clinicopathological value of HIF-1α in glioblastoma patients: a systematic review and meta-analysis},
  journal = {Neurosurgical Review},
  year = {2024},
  doi = {10.1007/s10143-024-03087-4}
}
Kostenlos starten →